Study Finds Ketamine Safe for Use in Managing Treatment-Resistant Depression

September 17, 2021 13:05:54

New research conducted by researchers from the Federal University of Bahia has found that ketamine and esketamine may be used safely as a treatment for depression. Ketamine is a synthetic compound used as an anesthesia drug while esketamine is an anesthetic that has been used to manage treatment-resistant depression. Ketamine is sometimes abused as a club drug and is popularly referred to as Special K and K in this scenario.

Various studies suggest that low doses of ketamine offer rapid antidepressant effects, improving a patient’s mood within 24 hours. Esketamine has been shown to possess similar benefits. A version of this drug was recently approved by the U.S. Food and Drug Administration (“FDA”) for use in individuals with depression that doesn’t respond to traditional antidepressants. While ketamine has not been approved to treat depression, some physicians prescribe it off label.

For their study, the Brazilian researchers conducted an analysis of 14 studies that included more than 1,000 patients who suffer from treatment-resistant depression. The participants were treated with esketamine or ketamine, and the objective of the study was to determine the cognitive safety of esketamine and ketamine.

The researchers evaluated six studies that administered ketamine infusions to patients, seven that administered one ketamine IV infusion to patients and one studty that administered esketamine nasal spray to patients for 44 weeks. While five of the ketamine studies reported improvements in cognitive flexibility, processing speed and memory, the esketamine study demonstrated no changes in cognitive performance in patients.

Cognitive flexibility refers to the ability to switch between thoughts or mental tasks while processing speed is the time it takes an individual to finish a mental task.

Of the 14 studies, only one reported cognitive impairment after ketamine had been administered. However, the researchers note in their review that the issues didn’t last more than a week after the drug’s administration. The review was published in the latest issue of the “Harvard Review of Psychiatry” journal. In a journal news release, the Brazilian researchers added that they observed some improvements in some cognitive functions a week to 13 days after ketamine infusions had been administered.

Lucas Quarantini and Breno Souza-Marques, both from the esteemed institution, which is located in Salvador Brazil, as well their colleagues, noted in their report that present evidence suggested that esketamine and ketamine didn’t exert any harmful neurocognitive effects in treatment-resistant depression. In their conclusion, the researchers argue that more studies should be conducted in the future.

Conducting more research is what companies such as Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) are doing in a bid to establish how different psychedelic compounds, including ketamine and psilocybin, can be used therapeutically.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.